ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance

FGF/FGFR gene aberrations such as amplification, mutation and fusion are associated with many types of human cancers including urothelial cancer. FGFR kinase inhibitors are expected to be a targeted therapy for urothelial cancer harboring FGFR3 gene alternations. ASP5878, a selective inhibitor of FG...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikuchi, Aya, Suzuki, Tomoyuki, Nakazawa, Taisuke, Iizuka, Masateru, Nakayama, Ayako, Ozawa, Tohru, Kameda, Minoru, Shindoh, Nobuaki, Terasaka, Tadashi, Hirano, Masaaki, Kuromitsu, Sadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329164/
https://www.ncbi.nlm.nih.gov/pubmed/27885740
http://dx.doi.org/10.1111/cas.13124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329164/
https://www.ncbi.nlm.nih.gov/pubmed/27885740
http://dx.doi.org/10.1111/cas.13124

Ejemplares similares